Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity

NCT07423481 · Not yet recruiting

Last updated 2026-05-28

This clinical trial studies how weight changes over time in adults with severe obesity or obesity-related complications after taking semaglutide.

Status Not yet recruiting Approved but enrollment has not started.

Type Observational

Participants 3,000 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-06 · est. completion 2027-03

Where 1 site · France

What this study is testing ClinicalTrials.gov NCT07423481 ↗

Description as written by the study sponsor.

SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.

Treatments tested

SEMAFOLLOW questionnaire Other

If the patient agrees, the center will send a link to the questionnaires via email. Patients who have completed the questionnaires will be analyzed in the SEMAFOLLOW study. Estimated time to complete the questionnaire: approximately 30 minutes

Main thing measured	Describe weight changes during the follow-up period according to patient characteristics.
Sponsor	Nantes University Hospital
Conditions studied	Obesity & Overweight
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07423481 ↗